Abstract
Limiting the development of secondary damage represents one of the major goals of neuroprotective therapies after spinal cord injury. Here, we demonstrate that specific JNK inhibition via a single intraperitoneal injection of the cell permeable peptide D-JNKI1 6h after lesion improves locomotor recovery assessed by both the footprint and the BMS tests up to 4 months post-injury in mice. JNK inhibition prevents c-jun phosphorylation and caspase-3 cleavage, has neuroprotective effects and results in an increased sparing of white matter at the lesion site. Lastly, D-JNKI1 treated animals show a lower increase of erythrocyte extravasation and blood brain barrier permeability, thus indicating protection of the vascular system. In total, these results clearly point out JNK inhibition as a promising neuroprotective strategy for preventing the evolution of secondary damage after spinal cord injury.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Blood Vessels / drug effects
-
Blood Vessels / physiology
-
Blotting, Western
-
Caspase 3 / metabolism
-
Hindlimb / physiology
-
Image Processing, Computer-Assisted
-
Imaging, Three-Dimensional
-
Immunohistochemistry
-
Injections, Intraperitoneal
-
JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors*
-
Locomotion / drug effects*
-
Male
-
Mice
-
Nerve Fibers / physiology
-
Neuroprotective Agents*
-
Peptides / pharmacology*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / pharmacology*
-
Proto-Oncogene Proteins c-jun / metabolism
-
Recovery of Function / drug effects*
-
Serotonin / physiology
-
Signal Transduction / drug effects*
-
Spinal Cord / pathology
-
Spinal Cord Injuries / drug therapy*
-
Spinal Cord Injuries / enzymology
-
Spinal Cord Injuries / physiopathology
Substances
-
Neuroprotective Agents
-
Peptides
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins c-jun
-
Serotonin
-
JNK Mitogen-Activated Protein Kinases
-
Caspase 3
-
D-JNKI-1